Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series

https://doi.org/10.1186/s13054-020-03078-z

This is the first report on nafamostat mesylate treatment in combination with favipiravir against Covid-19. No interruption of antiviral treatment occurred due to adverse drug reactions except for one patient who developed hyperkalemia on day 9 (by nafamostat mesylate). All 11 patients had at least 33 days of hospital follow-up. As of May 22, 1 patient, who had a do-not-resuscitate order, died on ICU day 7. Seven patients were successfully weaned from MV [median duration of MV 16 days (IQR, 10 to 19 days)] and 9 and 7 patients were discharged from the ICU and the hospital, respectively.

Tags: ,